Funded Research - GO2 for Lung Cancer

2013 Funded Research

Research Study: ALCMI Collaborative Advanced Stage Tissue Lung Cancer Network (CASTLE)

Researcher/Institution: 10 US and International Academic Institutions & 9 Community Hospitals. ALCMI – the only international consortium advancing lung cancer research by combining scientific expertise found at academic institutions with patient access through our network of community cancer centers.
Benefit to Patients: Free molecular testing for all enrolled patients results in more informed therapeutic decision-making by patients and their physicians.

Research Study: ALCMI INHERIT EGFR T790M
Researcher/Institution: Geoffrey Oxnard, MD, Dana-Farber Cancer Institute
Benefit to Patients: Potential discovery of inherited genetic marker could help identify families at risk

Research Study: ALCMI Genomics of Young Lung Cancer
Researcher/Institution: Barbara Gitlitz, MD, U. of Southern California
Benefit to Patients: Determine whether young lung cancers harbor a distinctive spectrum of genetic mutations requiring distinct treatment strategies

2012 Funded Research

Research Study: ROS1 Gene
Researcher/Institution: Ross Camidge, MD, Univ. of Colorado
Benefit to Patients: Potential genetic marker and possible druggable target

Research Study: Mouse Model tumor xenografts
Researcher/Institution: Phil Mack, PhD, Univ. of California, Davis
Benefit to Patients: Personalizing patient treatment – identify potential treatments via a mouse model with actual patient tumor to determine future therapies

Research Study: NF KappaB
Researcher/Institution: Collin Blakely, PhD, Univ. of California, San Francisco
Benefit to Patients: Potential discovery of new therapeutic target that could be druggable, offering patients additional treatment option

Research Study: KRAS
Researcher/Institution: Frederick Wilson, PhD, Dana Farber Cancer Institute
Benefit to Patients: Potential discovery of new therapeutic target that could be druggable, offering patients additional treatment option

Research Study: LKB1
Researcher/Institution: David Shackelford, PhD, Univ. of California, Los Angeles
Benefit to Patients: Potential genetic marker and possible druggable target

Research Study: EGFR & TK1
Researcher/Institution: Sohei Nakayana, PhD, Beth Israel Cancer Center
Benefit to Patients: Potential genetic marker and possible druggable target

Research Study: T790M
Researcher/Institution: Geoffrey Oxnard, MD, Dana Farber Cancer Institute
Benefit to Patients: Potential discovery of inherited genetic marker could help identify families at risk

Research Study: EGFR TKI1 vs., Chemotherapy
Researcher/Institution: Rafael Rosell, MD, PhD, Catalan Institute of Oncology, Hospital Germans I Pujol, Barcelona Spain
Benefit to Patients: Potential discovery of EGFR T790M acquired resistance and potential novel treatments

Research Study: International Chemotherapy Trial
Researcher/Institution: Giorgio Scagliotti, MD. PhD, Univ. of Turin, Italy
Benefit to Patients: Phase III Multicenter Randomized Trial comparing Adjuvant Pharmacogenomics-driven chemo vs. Standard Adjuvant chemo in completely resected stage II-IIIA non-small cell – 25 sites in Italy, Germany and Poland

Research Study: Collaborative Advanced Stage Tissue Lung Cancer Network (CASTLE)
Researcher/Institution: 10 US and International Academic Institutions & 9 Community Hospitals. ALCMI – the only international consortium advancing lung cancer research by combining scientific expertise found at academic institutions with patient access through our network of community cancer centers.
Benefit to Patients: Free molecular testing for all enrolled patients results in more informed therapeutic decision-making by patients and their physicians.

2011 Funded Research

Research Study: Discovery/Validation of Serum Micro RNAs
Researcher/Institution: Guoan Chen, PhD, Univ. of Michigan
Benefit to Patients: Potential early detection process

Research Study: S2R (Pgrmc!)
Researcher/Institution: Rolf Craven, PhD, Markey Cancer Center College of Medicine, Lexington, KY
Benefit to Patients: Potential therapeutic target for erlotinib-resistant lung cancer

Research Study: Tumor Genetic Discovery
Researcher/Institution: Carlo C. Maley, PhD, UCSF Helen Diller Family Comprehensive Cancer Center
Benefit to Patients: Potential to predict genetic diversity at treatment and survivability

Research Study: Early Detection
Researcher/Institution: Jiantao Pu, PhD, Univ. of Pittsburgh
Benefit to Patients: Potential novel computer-aided diagnosis paradigm

Research Study: Hedgehog
Researcher/Institution: Univ. of Texas, Southwestern Medical Center

Research Study: Collaborative Advanced Stage Tissue Lung Cancer Network (CASTLE)
Researcher/Institution: 10 US and International Academic Institutions & 9 Community Hospitals. ALCMI – the only international consortium advancing lung cancer research by combining scientific expertise found at academic institutions with patient access through our network of community cancer centers
Benefit to Patients: Free molecular testing for vall enrolled patients results in more informed therapeutic decision-making by patients and their physicians.

Research Study: Molecular Genetics
Researcher/Institution: Allan Balmain, PhD, Univ. of California, San Francisco
Benefit to Patients: Potential systematic approach toward individual diagnosis and treatment

Research Study: Personalizing Therapy
Researcher/Institution: Phil Mack, PhD, Univ. of California, Davis

2010 Funded Research

Research Study: Gene sequencing
Researcher/Institution: Joel Neal, MD, PhD, Stanford University

Research Study: Mouse Model tumor xenografts
Researcher/Institution: David Gandara, MD PhD, Univ. of California, Davis
Benefit to Patients: Personalizing patient treatment – identify potential treatments via a mouse with actual patient tumor to determine future therapies

Research Study: ALK Gene
Researcher/Institution: Robert Doebele, MD, PhD, Univ. of Denver, CO
Benefit to Patients: Potential novel techniques to identify ALK gene to improve survival

Research Study: Non-invasive thoracic surgery
Researcher/Institution: Chuong Hoang, MD, Stanford University
Benefit to Patients: Cardio-Thoracic surgery as means for early detection via non-invasive methods

Research Study: Collaborative Advanced Stage Tissue Lung Cancer Network (CASTLE)
Researcher/Institution: 10 US and International Academic Institutions & 9 Community Hospitals. ALCMI – the only international consortium advancing lung cancer research by combining scientific expertise found at academic institutions with patient access through our network of community cancer centers
Benefit to Patients: Free molecular testing for all enrolled patients results in more informed therapeutic decision-making by patients and their physicians.

2009 Funded Research

Research Study: Molecular Profiling
Researcher/Institution: Phil Mack, PhD, Univ. of California, Davis
Benefit to Patients: Potential predictive utility of molecular profiling of tumor and plasma specimens

Research Study: Creation of the Addario Lung Cancer Medical Institute
Researcher/Institution: ALCMI – the only international consortium advancing lung cancer research by combining scientific expertise found at academic institutions with patient access through our network of community cancer centers

2008 Funded Research

Research Study: Genomics
Researcher/Institution: Ite A. Laird-Offringa, PhD, Univ. of Southern California, Norris Comprehensive Cancer Center
Benefit to Patients: Genome discovery for DNA-silencing methylation changes during progression of lung adenocarcinoma

Research Study: Molecular Profiling
Researcher/Institution: Philip Mack, PhD, Univ. of California, Davis
Benefit to Patients: Potential predictive utility of molecular profiling of tumor and plasma specimens

Research Study: Early Detection
Researcher/Institution: Paul Scheinberg, MD, St. Joseph’s Hospital, Atlanta, GA
Benefit to Patients: Utilization of highly reliable screening technology

Research Study: Virtual Database Repository
Researcher/Institution: ALCMI
Benefit to Patients: Summit of 29 thought leaders gathered to develop and implement a strategic plan around a virtual blood and tissue sample repository

Research Study: Tumor immunology
Researcher/Institution: James Mulshine, MD, Rush University Medical Center
Benefit to Patients: Improve outcomes in patients via clinical trials for non-small cell, via tumor immunology and intervention research

Research Study: EGFR mutations
Researcher/Institution: Pasi Janne, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Benefit to Patients: Study of epidermal growth factor receptor (EGFR) and impact of EGFR-targeted therapeutic agents

Research Study: Advanced Diagnostics
Researcher/Institution: Larry Heifetz, MD, Tahoe Forest Medical Center, Truckee, CA
Benefit to Patients: Utilization of technology to advance new therapies

Research Study: Women’s Susceptibility
Researcher/Institution: Jill Siegfried, PhD, Univ. of Pittsburgh
Benefit to Patients: Identifying factors related to women’s increased susceptibility to lung cancer

Research Study: Immunotherapy
Researcher/Institution: David Carbone, MD, PhD, Vanderbilt-Ingram Cancer Center
Benefit to Patients: Immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy with translation to potential therapies

2007 Funded Research

Research Study: Early Detection
Researcher/Institution: Sequoia Hospital, Redwood City, CA
Benefit to Patients: Comprehensive lung cancer program – program coordinator to assist high-risk lung cancer patients in community setting

2006 Funded Research

Young Investigators

Research Study: Hedgehog pathway
Researcher/Institution: James Kim, MD, PhD, Harmon Center for Therapeutic Oncology Research, Dallas, TX
Benefit to Patients: Determine relationship between mutant KRAS and Hh pathway with potential therapeutic treatment regimens

Research Study: PARP Inhibition
Researcher/Institution: Naveen Kommajosyula, PhD, Dana-Farber Cancer Institute, Boston, MA
Benefit to Patients: Potential discovery of PARP inhibitor sensitivity

Lectureship Awards

Physician’s Education Resource (PER)
2012 International Lung Cancer Congress

Physician’s Education Resource (PER)
2011 International Lung Cancer Congress

Physician’s Education Resource (PER)
2010 International Lung Cancer Congress

Physician’s Education Resource (PER)
2009 International Lung Cancer Congress

Physician’s Education Resource (PER)
2008 International Lung Cancer Congress
Comprehensive programs designed to utilize advanced adult educational principles to ensure excellence in patient care

Physician’s Education Resource (PER)
2007 International Lung Cancer Congress
Comprehensive programs designed to utilize advanced adult educational principles to ensure excellence in patient care